Navigation Links
Launch of Novel Agents for the Treatment of Hepatitis C Virus Will Precipitate Treatment of At Least Half of 'Warehoused' Patients
Date:9/27/2010

BURLINGTON, Mass., Sept. 27 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the launch of novel therapies for the treatment of Hepatitis C Virus (HCV), including Vertex/Johnson & Johnson/Mitsubishi Tanabe's telaprevir and Merck's boceprevir, will precipitate several changes in HCV treatment. According to Patient Flow in Hepatitis C Virus, surveyed physicians plan to initiate treatment in at least half of their "warehoused" HCV1 patients one year after novel therapies become available. Patient "warehousing" is a term that has been coined to characterize the phenomenon of HCV patients opting out of treatment with current standard of care in anticipation of new therapies; psychiatric events, adverse events and liver health are top reasons keeping patients away from current therapies.

The report also finds that time from initial diagnosis to treatment initiation will decrease once novel HCV therapies are available. On average, surveyed physicians stated they wait 17 months to initiate treatment in HCV1 treatment-naive patients; this time will decrease to 7 months once novel treatment options are available.

"The arrival of telaprevir and boceprevir will alter more than the drug-treatment rate and treatment initiation timing in HCV," said Alexandra Makarova, M.D., Ph.D. "Physicians indicate they would increase the capacity of their HCV practice to accommodate the additional patients expected once novel therapies are available."

About Patient Flow in Hepatitis C VirusPatient Flow in Hepatitis C Virus is a 15-year, annualized patient forecast for each of the G7 countries that estimates the total size of the declining prevalent HCV population and segments it by viremic status, HCV genotype and line of therapy. It includes two components: an Excel workbook containing quantitative analysis, including patient forecast and modifiable assumptions and a PowerPoint slide deck of primary research survey results of 100 U.S. gastroenterologists and hepatologists.

About Decision ResourcesDecision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.For more information, contact:Decision ResourcesLisa Osgood781-993-2606losgood@dresources.comDecision Resources, Inc.Chris Comfort781-993-2597ccomfort@dresources.com
'/>"/>

SOURCE Decision Resources
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. New Smartphone App Launches for Cardiac Imaging Test
2. Effectively Educating the Marketplace to Support a Successful New Oncology Product Launch
3. Newly Re-launched Website Helps PhDs and MDs Capitalize on Growth in Life Science Industries
4. Elsevier Launches International Journal of Surgery Case Reports
5. Biomatrica Launches DNAgard® Blood and DNAstable Blood for Stabilization, Storage and Shipping of Whole Blood at Room Temperature
6. Pittsburgh Life Sciences Greenhouse Executive-in-Residence Launches Medical Device Company
7. Volcano Drives Innovation Forward With Three New U.S. Product Launches at TCT 2010
8. Roche Launches New Initiative - Roche Goes to Town
9. Medical Cannabis University™ Launches, Puts Thousands Back to Work to Help Veterans and the Chronically Ill
10. Olympus Launches 2011 National Innovation Awards Program
11. Access Pharmaceuticals Launches MuGard Product Website
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/19/2017)... , Tenn. and DALLAS , April 19, ... Inc., announced that the first patients in ... EndoStim device in the Lower Esophageal Sphincter Stimulation for ... minimally-invasive implantable device designed to provide long-term reflux control ... GERD affects nearly 65 million people in ...
(Date:4/19/2017)... , April 19, 2017  Novartis today announced ... National Heart, Lung, and Blood Institute (NHLBI) of ... 58% of patients with treatment-naïve severe aplastic anemia ... treated with eltrombopag at the initiation of and ... study evaluated three sequential treatment groups, or cohorts. ...
(Date:4/18/2017)... 18, 2017 Research and Markets has announced ... report to their offering. ... global arthroscopy devices market to grow at a CAGR of 6.35% ... Devices Market 2017-2021, has been prepared based on an in-depth market ... landscape and its growth prospects over the coming years. The report ...
Breaking Medicine Technology:
(Date:4/28/2017)... ... ... The Radiology Business Management Association (RBMA) is pleased to announce ... process has been in place since the RBMA was founded in 1968 with all ... Jim Hamilton, MHA, CMM, FRBMA, as president. Dr. Dickerson the chief executive officer for ...
(Date:4/28/2017)... ... April 28, 2017 , ... ... and College of Urgent Care Medicine will host industry leaders for the annual ... will help those in the industry adapt to the issues currently affecting urgent ...
(Date:4/28/2017)... ... , ... Yisrayl Hawkins, Pastor and Overseer at The House of Yahweh in Abilene, Texas, has ... which He does not. Yisrayl says with so many titles and names for the ... he says with a little Scripture, backed with a lot of research, the truth is ...
(Date:4/28/2017)... (PRWEB) , ... April 28, 2017 , ... ... skincare and advanced nutraceutical supplements, through its Nova Skin Sciences division, recently ... hydrating benefits of a moisturizer with the power of an anti-aging concentrate. ...
(Date:4/28/2017)... ... 2017 , ... Christie Medical Holdings, Inc. , with its market-leading ... Medical Inc. , a leader in infusion therapy and pain management. , Intravenous ... percent of hospital patients receiving a peripheral IV catheter as part of their treatment ...
Breaking Medicine News(10 mins):